HomeAbout UsPortfolioNewsContact Us

  • POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES

    Domain expertise, global resource, long-term capital

  • PORTFOLIO NEWS

    Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors
    2023年6月2日
    SHANGHAI, China and HAYWARD, Calif., June 1, 2023 – IMPACT Therapeutics (“Impact”), a...
    Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis
    2023年5月15日
      SHANGHAI, May 15, 2023 /PRNewswire/ -- Rona Therapeutics, Inc ("Rona") and Keymed Biosciences...
    Alebund Pharmaceuticals Closes Nearly RMB 200 Million Pre-C Round Financing and Secures RMB 800 Million Syndicated Loan Credit
    2023年4月12日
        Shanghai, China, April 12th, 2023—Alebund Pharmaceuticals (“Alebund” or the “Company”)...
    IMPACT Therapeutics Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint
    2023年4月12日
        SHANGHAI, China, April 11, 2023 -- IMPACT Therapeutics, Inc. (“IMPACT Therapeutics”),...
    BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
    2023年4月4日
      BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug...
    ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing
    2023年3月28日
        Funding from new and existing investors will support pivotal Phase 3 and additional studies...
    China’s NMPA Clears Phase 3 IND Application for Alebund Pharmaceutical’s AP301, a New-generation Iron-based Phosphate Binder, to Treat Hyperphosphatemia in Dialysis Patients
    2023年3月17日
    March 17, 2023, Shanghai, China—Alebund Pharmaceuticals (“Alebund” or the “Company”) announced...
    Eluminex Biosciences Closes $40+ Million Series B Financing to Continue the Development of Innovative Ophthalmic Assets and Recombinant Human Collagen Technology
    2023年2月28日
      SUZHOU, China and SAN FRANCISCO, Feb. 27, 2023 /PRNewswire/ -- Eluminex Biosciences (Suzhou)...
    More Posts
    All Posts
    ×
    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More